MedTrace Logo

Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.

NCT01887626 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2013-09-18

No results posted yet for this study

Summary

Study to investigate if the uptake of Ticagrelor into the body differs depending on method of administration.

Conditions

  • Bioavailability Heathy Volunteers

Interventions

DRUG

Ticagrelor 90 mg whole tablet

Ticagrelor 90 mg whole tablet administered as a single oral dose

DRUG

Ticagrelor 90 mg tablet crushed

Ticagrelor 90 mg crushed and suspended in water

DRUG

Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube

Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach

Sponsors & Collaborators

Principal Investigators

  • Judith Hsia, MD · AstraZeneca, Wilmington, US

  • Mirjana Kujacic, MD · AstraZeneca Mölndal, Sweden

  • Saeed Kahn, MBBS · Quintiles London, United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01887626 on ClinicalTrials.gov